CRSP
Price
$83.99
Change
-$2.20 (-2.55%)
Updated
Feb 23, 6:59 PM EST
65 days until earnings call
DNLI
Price
$16.93
Change
+$0.10 (+0.59%)
Updated
Feb 23, 6:59 PM EST
One day until earnings call
Ad is loading...

Analysis and predictions CRSP vs DNLI

Header iconCRSP vs DNLI Comparison
Open Charts CRSP vs DNLIBanner chart's image
CRISPR Therapeutics AG
Price$83.99
Change-$2.20 (-2.55%)
Volume$1.14M
CapitalizationN/A
Denali Therapeutics
Price$16.93
Change+$0.10 (+0.59%)
Volume$601.5K
CapitalizationN/A
View a ticker or compare two or three
CRSP vs DNLI Comparison Chart

Loading...

DNLIDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
CRSP vs. DNLI commentary
Feb 26, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRSP is a Hold and DNLI is a Hold.

COMPARISON
Comparison
Feb 26, 2024
Stock price -- (CRSP: $83.99 vs. DNLI: $16.93)
Brand notoriety: CRSP and DNLI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRSP: 91% vs. DNLI: 105%
Market capitalization -- CRSP: $6.74B vs. DNLI: $2.34B
CRSP [@Biotechnology] is valued at $6.74B. DNLI’s [@Biotechnology] market capitalization is $2.34B. The market cap for tickers in the [@Biotechnology] industry ranges from $550.21B to $0. The average market capitalization across the [@Biotechnology] industry is $2.58B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRSP’s FA Score shows that 0 FA rating(s) are green whileDNLI’s FA Score has 0 green FA rating(s).

  • CRSP’s FA Score: 0 green, 5 red.
  • DNLI’s FA Score: 0 green, 5 red.
According to our system of comparison, CRSP is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 4 TA indicator(s) are bullish.

  • DNLI’s TA Score: 4 bullish, 4 bearish.

Price Growth

CRSP (@Biotechnology) experienced а +2.15% price change this week, while DNLI (@Biotechnology) price change was -0.53% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.03%. For the same industry, the average monthly price growth was +18.51%, and the average quarterly price growth was +38.88%.

Reported Earning Dates

CRSP is expected to report earnings on Apr 30, 2024.

DNLI is expected to report earnings on May 02, 2024.

Industries' Descriptions

@Biotechnology (+2.03% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for CRSP with price predictions.
OPEN
A.I.dvisor published
a Summary for DNLI with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
CRSP($6.74B) has a higher market cap than DNLI($2.34B). DNLI has higher P/E ratio than CRSP: DNLI (62.89) vs CRSP (20.92). CRSP YTD gains are higher at: 34.169 vs. DNLI (-21.109). DNLI has higher annual earnings (EBITDA): -150.83M vs. CRSP (-202.7M). CRSP has more cash in the bank: 1.69B vs. DNLI (1.11B). DNLI has less debt than CRSP: DNLI (53.9M) vs CRSP (239M). CRSP has higher revenues than DNLI: CRSP (370M) vs DNLI (341M).
CRSPDNLICRSP / DNLI
Capitalization6.74B2.34B288%
EBITDA-202.7M-150.83M134%
Gain YTD34.169-21.109-162%
P/E Ratio20.9262.8933%
Revenue370M341M109%
Total Cash1.69B1.11B153%
Total Debt239M53.9M443%
FUNDAMENTALS RATINGS
CRSP vs DNLI: Fundamental Ratings
CRSP
DNLI
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
66
Overvalued
80
Overvalued
PROFIT vs RISK RATING
1..100
65100
SMR RATING
1..100
9390
PRICE GROWTH RATING
1..100
3681
P/E GROWTH RATING
1..100
7895
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRSP's Valuation (66) in the Biotechnology industry is in the same range as DNLI (80). This means that CRSP’s stock grew similarly to DNLI’s over the last 12 months.

CRSP's Profit vs Risk Rating (65) in the Biotechnology industry is somewhat better than the same rating for DNLI (100). This means that CRSP’s stock grew somewhat faster than DNLI’s over the last 12 months.

DNLI's SMR Rating (90) in the Biotechnology industry is in the same range as CRSP (93). This means that DNLI’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's Price Growth Rating (36) in the Biotechnology industry is somewhat better than the same rating for DNLI (81). This means that CRSP’s stock grew somewhat faster than DNLI’s over the last 12 months.

CRSP's P/E Growth Rating (78) in the Biotechnology industry is in the same range as DNLI (95). This means that CRSP’s stock grew similarly to DNLI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLI
RSI
ODDS (%)
Bullish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
75%
Momentum
ODDS (%)
Bearish Trend 3 days ago
82%
MACD
ODDS (%)
Bullish Trend 3 days ago
81%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
85%
Advances
ODDS (%)
Bullish Trend 3 days ago
79%
Declines
ODDS (%)
Bearish Trend 5 days ago
82%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
76%
Aroon
ODDS (%)
Bearish Trend 3 days ago
85%
View a ticker or compare two or three
Ad is loading...
DNLIDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GTLIX23.030.05
+0.22%
Glenmede Quant US Large Cap Core EqInstl
CTSOX29.360.01
+0.03%
Calamos Timpani Small Cap Growth R6
EGFIX48.60-0.03
-0.06%
Edgewood Growth Instl
PPNPX13.03-0.01
-0.08%
Principal SmallCap Growth I R5
FARLX11.74-0.02
-0.17%
FS Chiron Real Development A

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been closely correlated with NTLA. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if DNLI jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
+0.59%
NTLA - DNLI
68%
Closely correlated
-3.97%
BEAM - DNLI
65%
Loosely correlated
+1.34%
VCYT - DNLI
61%
Loosely correlated
-8.87%
EDIT - DNLI
59%
Loosely correlated
-1.51%
ADPT - DNLI
54%
Loosely correlated
+4.12%
More